"Cytochrome P-450 CYP3A" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A cytochrome P-450 suptype that has specificity for a broad variety of lipophilic compounds, including STEROIDS; FATTY ACIDS; and XENOBIOTICS. This enzyme has clinical significance due to its ability to metabolize a diverse array of clinically important drugs such as CYCLOSPORINE; VERAPAMIL; and MIDAZOLAM. This enzyme also catalyzes the N-demethylation of ERYTHROMYCIN.
| Descriptor ID |
D051544
|
| MeSH Number(s) |
D08.244.453.860.500 D08.811.682.662.582.353 D08.811.682.690.708.170.495.500 D12.776.422.220.453.860.500
|
| Concept/Terms |
Cytochrome P-450 CYP3A- Cytochrome P-450 CYP3A
- Cytochrome P 450 CYP3A
- P-450 CYP3A, Cytochrome
- Cytochrome P-450IIIA
- Cytochrome P 450IIIA
- P-450IIIA, Cytochrome
- Erythromycin N-Demethylase
- Erythromycin N Demethylase
- N-Demethylase, Erythromycin
- CYP3A
- Cytochrome P450 3A
- P450 3A, Cytochrome
Cytochrome P-450 CYP3A5- Cytochrome P-450 CYP3A5
- Cytochrome P 450 CYP3A5
- P-450 CYP3A5, Cytochrome
- CYP3A5
- Cytochrome P450 3A5
- 3A5, Cytochrome P450
- P450 3A5, Cytochrome
Cytochrome P-450 CYP3A4- Cytochrome P-450 CYP3A4
- Cytochrome P 450 CYP3A4
- P-450 CYP3A4, Cytochrome
- Cytochrome P450 3A4
- Taurochenodeoxycholate 6-alpha-Monooxygenase
- 6-alpha-Monooxygenase, Taurochenodeoxycholate
- Taurochenodeoxycholate 6 alpha Monooxygenase
- CYP3A4
|
Below are MeSH descriptors whose meaning is more general than "Cytochrome P-450 CYP3A".
Below are MeSH descriptors whose meaning is more specific than "Cytochrome P-450 CYP3A".
This graph shows the total number of publications written about "Cytochrome P-450 CYP3A" by people in this website by year, and whether "Cytochrome P-450 CYP3A" was a major or minor topic of these publications.
View timeline visualization
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 2 | 2 |
| 1996 | 0 | 4 | 4 |
| 1997 | 0 | 4 | 4 |
| 1998 | 0 | 11 | 11 |
| 1999 | 0 | 10 | 10 |
| 2000 | 0 | 5 | 5 |
| 2001 | 0 | 12 | 12 |
| 2002 | 0 | 9 | 9 |
| 2003 | 0 | 12 | 12 |
| 2004 | 0 | 10 | 10 |
| 2005 | 1 | 13 | 14 |
| 2006 | 2 | 23 | 25 |
| 2007 | 4 | 11 | 15 |
| 2008 | 8 | 8 | 16 |
| 2009 | 7 | 5 | 12 |
| 2010 | 8 | 1 | 9 |
| 2011 | 7 | 5 | 12 |
| 2012 | 7 | 8 | 15 |
| 2013 | 6 | 4 | 10 |
| 2014 | 6 | 11 | 17 |
| 2015 | 4 | 3 | 7 |
| 2016 | 1 | 5 | 6 |
| 2017 | 2 | 4 | 6 |
| 2018 | 3 | 2 | 5 |
| 2019 | 4 | 1 | 5 |
| 2020 | 2 | 5 | 7 |
| 2021 | 4 | 2 | 6 |
| 2022 | 2 | 3 | 5 |
| 2023 | 1 | 7 | 8 |
| 2024 | 1 | 0 | 1 |
Below are the most recent publications written about "Cytochrome P-450 CYP3A" by people in Profiles.
-
Interindividual variability in CYP3A-mediated venetoclax metabolism in vitro and in vivo in patients with chronic lymphocytic leukemia. Clin Transl Sci. 2024 Dec; 17(12):e70106.
-
Use of physiologically-based pharmacokinetic modeling to understand the effect of omeprazole administration on the pharmacokinetics of oral extended-release nifedipine. CPT Pharmacometrics Syst Pharmacol. 2024 02; 13(2):247-256.
-
Phase I Trial of the Multi-kinase Inhibitor Cabozantinib, a CYP3A4 Substrate, plus CYP3A4-Interacting Antiretroviral Therapy in People Living with HIV and Cancer (AMC-087). Clin Cancer Res. 2023 12 15; 29(24):5038-5046.
-
Tacrolimus Pharmacokinetics is Associated with Gut Microbiota Diversity in Kidney Transplant Patients: Results from a Pilot Cross-Sectional Study. Clin Pharmacol Ther. 2024 01; 115(1):104-115.
-
Drug interaction potential of high-dose rifampicin in patients with pulmonary tuberculosis. Antimicrob Agents Chemother. 2023 10 18; 67(10):e0068323.
-
Effects of CYP3A4 and CYP2C9 genotype on systemic anastrozole and fulvestrant concentrations in SWOG S0226. Pharmacogenomics. 2023 08; 24(12):665-673.
-
Gut microbiome modulates tacrolimus pharmacokinetics through the transcriptional regulation of ABCB1. Microbiome. 2023 07 06; 11(1):138.
-
Identification and kinetics of microsomal and recombinant equine liver cytochrome P450 enzymes responsible for in vitro metabolism of omeprazole. Biochem Pharmacol. 2023 08; 214:115635.
-
Vinblastine pharmacokinetics in mouse, dog, and human in the context of a physiologically based model incorporating tissue-specific drug binding, transport, and metabolism. Pharmacol Res Perspect. 2023 02; 11(1):e01052.
-
Nirmatrelvir/ritonavir Use With Tacrolimus in Lung Transplant Recipients: A Single-center Case Series. Transplantation. 2023 05 01; 107(5):1200-1205.